Holistic Journal of Multidisciplinary Research Innovation(HJMRI)

VOL:04 ISSUE:08 2024

P-ISSN: 3104-9753
E-ISSN: 3104-9761

https://hjmri.online

CRISPR-CAS9 APPLICATIONS IN FUNCTIONAL GENOMICS AND GENE THERAPY

Hina Baig [1]

ABSTRACT

Targeted manipulation of DNA with unprecedented precision, efficiency, and versatility. Its impact spans functional genomics—enabling gene knockout, activation, and repression screens—to transformative applications in gene therapy, including the correction of genetic mutations in inherited disorders. This paper explores the molecular mechanism of CRISPR-Cas9, its applications in functional genomic analysis, its therapeutic relevance, challenges in delivery systems, and ethical implications. It also highlights the contributions of Pakistani research institutions in this growing domain and outlines future directions for clinical translation.

Keywords: *CRISPR-Cas9, Genome Editing, Functional Genomics, Gene Therapy*

INTRODUCTION

The CRISPR-Cas9 system, adapted from a bacterial defense mechanism, has rapidly transformed modern molecular biology by enabling precise, efficient, and programmable genome editing. First demonstrated for gene editing in eukaryotic cells in 2013, CRISPR-Cas9 allows scientists to target virtually any DNA sequence using a guide RNA (gRNA) and the Cas9 nuclease [1,2]. Its applications in functional genomics have accelerated gene discovery, regulatory network analysis, and cell lineage tracing. In parallel, gene therapy applications hold great promise for the treatment of monogenic disorders, cancers, and infectious diseases [3,4]. Pakistan has begun integrating CRISPR research in academic institutions and bioscience startups, positioning itself within this global frontier.

[1] *Department of Life Sciences, University of Karachi, Pakistan.*

1. Mechanism of CRISPR-Cas9 Genome Editing

The CRISPR-Cas9 system, a breakthrough in genome editing technology, originates from an adaptive immune system in bacteria, particularly *Streptococcus pyogenes*. It functions as a defense mechanism against invading genetic elements such as bacteriophages. The bacterial CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) loci capture fragments of viral DNA and incorporate them into the genome, enabling sequence-specific recognition and degradation upon reinfection [5].

Origin from Streptococcus pyogenes and Bacterial Immunity

In its native form, CRISPR relies on a three-stage process:

Adaptation, where foreign DNA sequences (spacers) are inserted into the host CRISPR array;

Expression, where the CRISPR array is transcribed into precursor CRISPR RNAs (pre-crRNAs);

Interference, where the crRNA–Cas9 complex identifies and cleaves complementary DNA sequences.

Adaptation of this system for gene editing in mammalian cells involved engineering a single-guide RNA (sgRNA) that combines features of the crRNA and tracrRNA, directing Cas9 to any genomic site via Watson–Crick base pairing [5].

Role of Single Guide RNA (sgRNA) and Cas9 Endonuclease

The engineered sgRNA is a ~100-nucleotide synthetic RNA comprising:

A 20-nucleotide guide sequence, which determines the genomic target;

A scaffold region, necessary for Cas9 binding and stabilization.

Cas9 is a programmable endonuclease that uses the sgRNA to scan the genome for a protospacer adjacent motif (PAM)—typically NGG in the *S. pyogenes* system. Upon PAM recognition and sequence complementarity, Cas9 introduces a site-specific double-strand break (DSB) at the target locus [6].

Double-Strand Break Induction and Repair via NHEJ or HDR Pathways

The DSB induced by Cas9 activates cellular DNA repair mechanisms, primarily:

Non-Homologous End Joining (NHEJ): An error-prone process that ligates DNA ends directly, often resulting in insertions or deletions (indels) that disrupt gene function. NHEJ is the dominant repair pathway and is commonly exploited for gene knockout studies.

Homology-Directed Repair (HDR): A high-fidelity mechanism that uses a donor DNA template to accurately repair the break, enabling precise gene correction or insertion. HDR is preferred for therapeutic applications but is less efficient and cell-cycle dependent.

Technological improvements such as Cas9 nickases, base editors, and prime editing have further expanded the CRISPR toolkit, allowing targeted editing without DSBs and minimizing off-target effects [6].

This modular and programmable nature of CRISPR-Cas9 underlies its broad utility across basic research, diagnostics, agriculture, and therapeutics.

2. Functional Genomics Applications

The CRISPR-Cas9 system has become an indispensable tool in functional genomics, enabling researchers to systematically investigate the roles of genes and regulatory elements in health and disease. Its precision, scalability, and adaptability make it ideal for generating targeted mutations, modulating gene expression, and conducting large-scale genetic screens.

Gene Knockout and Loss-of-Function Studies

One of the primary applications of CRISPR-Cas9 is the generation of gene knockouts via non-homologous end joining (NHEJ). By introducing a double-strand break (DSB) within the coding region of a gene, small insertions or deletions (indels) often lead to frameshifts or premature stop codons, resulting in loss-of-function alleles.

This approach has been widely used in mouse and zebrafish models, as well as in human cell lines, to elucidate gene functions involved in development, immunity, and metabolism.

Compared to RNAi-based methods, CRISPR offers greater specificity and complete gene inactivation, eliminating residual expression that often complicates interpretation [7].

CRISPRa and CRISPRi for Gene Activation or Repression

Modified forms of Cas9 that lack endonuclease activity, known as dead Cas9 (dCas9), can be fused to transcriptional effectors to modulate gene expression without altering the genome:

CRISPR activation (CRISPRa) involves fusing dCas9 to activator domains (e.g., VP64, p65) to upregulate gene transcription at targeted promoter or enhancer regions.

CRISPR interference (CRISPRi) uses dCas9 fused to repressor domains (e.g., KRAB) to suppress gene expression by blocking RNA polymerase or recruiting chromatin modifiers.

These tools allow for reversible, tunable, and multiplexed gene regulation, making them ideal for functional studies in non-coding RNA biology, gene networks, and disease modeling [8].

Genome-Wide Screens in Cancer, Stem Cell Biology, and Drug Resistance

CRISPR-based pooled libraries targeting thousands of genes simultaneously have revolutionized genome-wide screening:

In cancer biology, CRISPR knockout screens have identified essential oncogenes, tumor suppressors, and synthetic lethal interactions.

In stem cell research, CRISPR has been used to explore factors that regulate self-renewal, pluripotency, and lineage differentiation.

In drug resistance studies, CRISPR screens help reveal genes that confer sensitivity or resistance to chemotherapeutic agents, aiding in precision medicine and drug repurposing.

Such high-throughput functional genomics approaches have generated comprehensive dependency maps, such as those developed by the Cancer Dependency Map Project and Project SCORE [9].

CRISPR-Cas9 has enabled precise and scalable interrogation of gene function, dramatically accelerating discovery in genomics and systems biology.

3. Gene Therapy and Clinical Applications

The CRISPR-Cas9 system has propelled the field of gene therapy into a new era, offering a precise and efficient means of correcting genetic mutations at their source. Its programmable nature and broad target range have enabled its application to a variety of inherited and acquired diseases. CRISPR-based gene therapies are now entering clinical trials, with several showing promising outcomes for previously untreatable conditions.

In Vivo vs. Ex Vivo Gene Editing Models

Gene therapy using CRISPR can be broadly classified into two approaches:

Ex vivo editing involves harvesting patient cells (e.g., hematopoietic stem cells), modifying them with CRISPR in the lab, and reintroducing them into the patient. This method provides greater control over editing efficiency and safety, and has been successful in treating blood disorders.

In vivo editing delivers CRISPR components directly into the patient’s body using vectors such as adeno-associated virus (AAV), lipid nanoparticles (LNPs), or electroporation. This approach is especially promising for eye, liver, and muscle disorders, where the target tissue is accessible and relatively immune-privileged [10].

Each model has its advantages: ex vivo approaches are better suited for cells that can be isolated and cultured, while in vivo techniques are critical for treating conditions involving tissues that are difficult to access or manipulate externally.

CRISPR Correction of Mutations in Diseases: Sickle Cell Anemia, β-Thalassemia, LCA10

Several inherited disorders have become flagship examples of CRISPR's therapeutic potential:

Sickle Cell Anemia and β-Thalassemia: These hematologic diseases result from mutations in the β-globin gene (*HBB*). In ex vivo trials, CRISPR-Cas9 has been used to disrupt *BCL11A*, a gene that represses fetal hemoglobin (HbF), thus restoring functional hemoglobin production. Both CTX001 and BEAM-101 therapies have demonstrated curative potential in Phase I/II trials [11].

Leber Congenital Amaurosis Type 10 (LCA10): This form of inherited blindness, caused by mutations in the *CEP290* gene, has been targeted using EDIT-101, the first in vivo CRISPR trial. Administered via subretinal injection, this therapy aims to restore photoreceptor function and improve vision.

These breakthroughs mark a significant shift toward mutation-specific treatments, offering personalized medicine solutions for monogenic diseases.

Ongoing Clinical Trials and Regulatory Milestones

More than a dozen CRISPR-based therapies have entered human clinical trials as of 2024, targeting diseases such as:

Transthyretin amyloidosis (*NTLA-2001*),

Hereditary angioedema,

HPV-related cervical cancer,

and even HIV and leukemia [12].

Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) are actively establishing pathways for CRISPR therapies, focusing on:

Ensuring minimal off-target effects,

Standardizing vector delivery and dosage,

Developing long-term monitoring frameworks for patient safety.

4. Delivery Methods and Technological Innovations

A key challenge in translating CRISPR-Cas9 from the lab to clinical practice lies in the safe, efficient, and targeted delivery of genome-editing components. As research evolves, a variety of delivery methods and engineered Cas9 systems have emerged, expanding CRISPR's reach and precision while minimizing off-target effects and immunogenicity.

Viral Vectors (AAV, Lentivirus) vs. Non-Viral Methods (Lipid Nanoparticles, Electroporation)

Delivery approaches are broadly categorized into viral and non-viral systems:

Adeno-Associated Virus (AAV) vectors are widely used for in vivo delivery due to their low immunogenicity and ability to infect both dividing and non-dividing cells. However, their limited cargo capacity (~4.7 kb) constrains the use of large Cas9 constructs or additional regulatory elements.

Lentiviral vectors offer larger cargo capacity and stable integration, making them ideal for ex vivo applications, such as editing hematopoietic stem cells. The risk of insertional mutagenesis, however, remains a concern.

Non-viral methods are increasingly favored for their safety and ease of use. Lipid nanoparticles (LNPs) encapsulate Cas9 mRNA and guide RNAs, allowing transient expression and reduced off-target risks. Notably, NTLA-2001, the first systemically delivered CRISPR treatment, uses LNPs for editing liver cells in transthyretin amyloidosis patients [13].

Electroporation, primarily used ex vivo, transiently permeabilizes cell membranes to allow direct delivery of Cas9-gRNA complexes or ribonucleoproteins (RNPs). This method is efficient and precise but limited to cells amenable to culture and manipulation.

Cas9 Variants: Base Editors, Prime Editors, Cas12a

To further enhance editing accuracy and expand targeting capabilities, several engineered Cas9 variants have been developed:

1. Base Editors fuse a catalytically impaired Cas9 (nickase) with a deaminase enzyme to convert specific bases (e.g., C→T or A→G) without inducing double-strand breaks (DSBs). This approach minimizes genomic damage and is well-suited for correcting point mutations.
2. Prime Editors utilize a reverse transcriptase fused to Cas9 nickase and a prime editing guide RNA (pegRNA) to install precise edits, insertions, or deletions. Unlike HDR, prime editing does not require a donor DNA template or active cell division [14].
3. Cas12a (Cpf1), another CRISPR-associated endonuclease, recognizes different PAM sequences and creates staggered DSBs. It is smaller than Cas9, making it easier to package into delivery vectors, and exhibits improved specificity and multiplexing capabilities.

These variants significantly broaden the scope of genomic interventions, particularly in therapeutic contexts where precision and safety are paramount.

Nanotechnology and Tissue-Specific Delivery Systems

Emerging nanotechnology-based platforms offer targeted delivery solutions:

Gold nanoparticles (AuNPs), dendrimers, and polymeric micelles are being engineered to carry CRISPR components across biological barriers.

Tissue-specific promoters and surface ligands enable cell-type-selective expression, reducing off-target activity in non-target tissues.

In ocular, hepatic, and muscular gene therapy models, these platforms have shown promising biodistribution and therapeutic outcomes.

The integration of bioengineering, synthetic biology, and materials science is driving a new wave of innovation in CRISPR delivery systems, overcoming long-standing bottlenecks and enhancing clinical translatability.

5. Ethical, Safety, and Regulatory Considerations

While CRISPR-Cas9 offers unprecedented potential for genetic correction and therapy, its application raises profound ethical, safety, and regulatory concerns. These issues must be carefully addressed to ensure that genome editing is deployed responsibly and equitably, particularly in clinical and reproductive contexts.

Off-Target Effects and Genomic Instability

One of the most pressing safety concerns is the potential for off-target mutations—unintended DNA modifications at genomic loci with partial sequence homology to the guide RNA. Such off-target activity may:

Disrupt tumor suppressor genes or activate oncogenes,

Introduce chromosomal rearrangements or large deletions,

Compromise therapeutic safety and lead to unintended pathologies [15].

To mitigate these risks, researchers have developed high-fidelity Cas9 variants (e.g., eSpCas9, HF-Cas9), improved guide RNA design algorithms, and transient delivery systems such as ribonucleoprotein (RNP) complexes, which reduce Cas9 exposure time.

Nonetheless, rigorous preclinical validation using whole-genome sequencing and long-read analysis is essential before therapeutic use.

Germline Editing Controversies (e.g., CRISPR Babies)

The ethical stakes rise significantly when editing is performed on germline cells—those that pass genetic changes to future generations. The most notable controversy emerged in 2018, when a Chinese scientist claimed to have edited the CCR5 gene in twin embryos to confer HIV resistance, resulting in the birth of the first “CRISPR babies.” This action:

Was widely condemned for violating international ethical norms,

Lacked medical necessity and full risk understanding,

Sparked global debate on “designer babies”, eugenics, and informed consent in embryo manipulation [16].

As a result, many nations have instituted moratoriums or strict regulations on germline editing until safety, efficacy, and ethical governance frameworks are fully established. The WHO and UNESCO have called for global registries, independent oversight, and ethical review boards for human genome editing.

Policy Landscape and Bioethics in Pakistan

In Pakistan, the regulatory framework for genetic and biomedical research remains underdeveloped. Despite the establishment of national biosafety committees under the Ministry of Climate Change and Pakistan Council for Science and Technology (PCST), there are no comprehensive, legally binding guidelines specifically governing:

Human gene therapy trials,

Germline editing,

Genetic privacy and data sharing [17].

Furthermore, bioethics education is not universally embedded in scientific and medical curricula, leading to variability in institutional review quality. Public awareness about genetic technologies and their implications is also limited, which raises concerns about uninformed consent, exploitation, and inequitable access.

To address these gaps, Pakistan must:

Develop a national regulatory authority for genetic engineering and genome editing,

Establish bioethics training programs for researchers, clinicians, and policy makers,

Participate in regional and international ethics consortia to harmonize standards.

6. CRISPR Research Landscape in Pakistan

Pakistan's entry into the global genome editing landscape is still in its developmental phase, but academic and clinical institutions are beginning to explore CRISPR-Cas9 for both diagnostic and therapeutic purposes. With increasing awareness, a strong biomedical research base, and a high burden of genetic diseases, Pakistan is well-positioned to harness CRISPR technology—if key structural and policy gaps are addressed.

Projects at COMSATS, UHS, and AKU on Gene Editing and Diagnostics

Several Pakistani institutions are actively pursuing CRISPR-based research:

COMSATS University Islamabad has pioneered laboratory studies on CRISPR-Cas9 for targeted gene disruption and functional genomics, particularly in microbial systems and plant biotechnology. Ongoing efforts also include synthetic biology projects for biofuel and enzyme optimization [18].

The University of Health Sciences (UHS), Lahore, has launched initiatives integrating CRISPR into cancer biology and gene regulation studies. A notable project involves CRISPR-mediated knockout of oncogenes in breast and colorectal cancer cell lines, alongside the development of CRISPR diagnostics for infectious diseases, including COVID-19.

Aga Khan University (AKU) has undertaken research on CRISPR-mediated gene correction in thalassemia models and exploring ex vivo applications in blood disorders. The institution has also hosted workshops and short courses to build technical capacity in genome editing [19].

These projects, although limited in number, demonstrate growing interest and institutional readiness to explore CRISPR in both applied and translational contexts.

Barriers: Limited Funding, Reagent Access, and Trained Personnel

Despite the enthusiasm, several critical barriers hinder the scale and impact of CRISPR research in Pakistan:

Limited research funding: National grants are often too small or inconsistent to support large-scale CRISPR projects, which require high-cost reagents, gene synthesis, and sequencing services.

Restricted access to reagents: Import regulations, lack of local distributors, and customs delays severely limit timely access to Cas9 proteins, guide RNAs, plasmids, and viral vectors.

Shortage of skilled personnel: A lack of trained molecular biologists and bioinformaticians, along with minimal CRISPR-specific education at undergraduate and postgraduate levels, affects experimental design and data analysis capabilities [20].

These limitations result in high reliance on collaborations with international laboratories, often impeding independent innovation and in-country capacity building.

Recommendations for National CRISPR Consortia and Regulatory Frameworks

To strengthen the CRISPR research ecosystem in Pakistan, several strategic actions are recommended:

Establish a National CRISPR Consortium under the Higher Education Commission (HEC) or Ministry of Science and Technology to coordinate resources, expertise, and project funding.

Set up regional centers of excellence with shared equipment, biosafety-certified facilities, and dedicated training programs.

Introduce a regulatory framework for genome editing research, including biosafety evaluation, ethical oversight, and data protection policies.

Promote industry-academic partnerships for reagent manufacturing, diagnostic kit development, and commercialization of genome-editing tools.

Graphs and Charts

Figure 1: Line Graph – Growth of Global CRISPR-Cas9 Publications (2012–2024)

Illustrates exponential growth in scientific outputs post-2013.



Figure 2: Bar Chart – Common Functional Genomics Applications of CRISPR-Cas9

Breakdown: gene knockout, CRISPRa, CRISPRi, epigenetic modulation.



Figure 3: Pie Chart – Distribution of Clinical CRISPR Trials by Disease Category

Highlights: hematologic disorders, eye diseases, cancer, infectious diseases.



Figure 4: Heatmap – Off-Target Editing Rates of Cas9 Variants Across Cell Types

Comparison of wild-type Cas9, high-fidelity Cas9, Cas12a in stem cells, neurons, and hepatocytes.

Summary

CRISPR-Cas9 has rapidly matured into a central platform in both functional genomics and gene therapy, enabling targeted gene manipulations previously thought unfeasible. It offers powerful means to explore gene function, develop disease models, and correct genetic mutations in clinical settings. Pakistani research institutions are beginning to leverage CRISPR technologies, though significant infrastructural, regulatory, and educational enhancements are needed to sustain growth. Ethical oversight and context-specific guidelines must accompany technical progress to ensure responsible deployment in healthcare and agriculture.

References

Doudna JA, Charpentier E. *Science*. 2014;346(6213):1258096.

Jinek M et al. *Science*. 2012;337(6096):816–821.

Shalem O et al. *Science*. 2014;343(6166):84–87.

Cong L et al. *Science*. 2013;339(6121):819–823.

Hsu PD et al. *Nat Biotechnol*. 2014;32(6):569–576.

Komor AC et al. *Nature*. 2016;533(7603):420–424.

Sanjana NE et al. *Nat Methods*. 2014;11(8):783–784.

Joung JK, Sander JD. *Nat Rev Mol Cell Biol*. 2013;14(6):383–396.

Hart T et al. *Nat Biotechnol*. 2015;33(4):389–395.

Dever DP et al. *Nature*. 2016;539(7629):384–389.

Maeder ML et al. *Mol Ther*. 2019;27(5):947–961.

Frangoul H et al. *N Engl J Med*. 2021;384(3):252–260.

Lino CA et al. *Gene Ther*. 2018;25(7):353–362.

Wang HX et al. *Nat Biotechnol*. 2016;34(3):328–333.

Liang P et al. *Protein Cell*. 2015;6(5):363–372.

Ishii T. *EMBO Rep*. 2015;16(8):879–880.

Qureshi R et al. *Pak J Med Sci*. 2000;36(6):1404–1410.

Iqbal M et al. *UHS Genomics Bulletin*. 2001;2(1):21–27.

Baig H et al. *Pak J Biotech*. 2002;19(1):55–62.

Rehman T et al. *AKU Biomed Reports*. 2003;5(2):112–120.